Intercept Pharmaceuticals | ICPT - L'Utile Ante Imposte



L'Utile Ante Imposte Cambiamento Data
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amarin USD -852K 7.26M 2025-12
Amgen USD 1.51B 2.41B 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
Biogen USD 377.7M 433.7M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Esperion Therapeutics USD 63.67M 95M 2025-12
Galectin Therapeutics USD -12.37M 880K 2024-06
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Incyte USD 389.94M 92.37M 2025-12
Ionis Pharmaceuticals USD -93M 135M 2026-03
Moderna USD -187M 631M 2025-09
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 4.64B 445M 2025-12
PTC Therapeutics USD -139.08M 116.01M 2025-12
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09